Hypoglycemia, a dangerous drop in blood glucose levels related to insulin and sulfonylurea (SU) use, has been identified as one of the top three preventable adverse drug events by the U.S. Department of Health and Human Services. Yet the prevalence and high burden of disease in patients with type 2 diabetes (T2D), particularly the elderly, are often underappreciated in clinical settings. Supporting the early identification and management of those at greatest risk is critical.
The Endocrine Society has made reducing the incidence of hypoglycemia a priority for a number of years. The Hypoglycemia Prevention Initiative is a multi-year joint effort of the Endocrine Society and Avalere Health to determine best practices in primary care to reduce the impact of hypoglycemia on older (65+) people with type 2 diabetes (T2D) who use insulin and/or sulfonylurea, have a recent A1c <7%, and are at increased risk of hypoglycemia. To learn more, visit the Hypoglycemia Prevention Initiative page.
From bench to bedside and all the stages in between, the Hormone Health Network is committed to supporting patient and public education.
Secure the most competitive pricing for ENDO by taking advantage of our Early Registration rates, available now for a limited time!
Join us as we plan for the future by renewing today! Renewing your membership is the best way to ensure that you remain a key part of our efforts to support the global endocrine community.
